Vanda Pharmaceuticals (VNDA)

• Market cap: $261M
• 1 day: -0.68%
• 5 days: 1.15%
• 1 month: -18.33%
• 3 months: 4.5%
• 6 months: 0.92%
• Year to date: -8.51%
• 1 year: -9.82%
• 5 years: -62.4%
• 10 years: -54.86%
• Sector: Healthcare
• Industry: Biotechnology

About: Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Employees: 368